November 18th, 2024: Ratio Enters License and Collaboration …

5 days ago · Ratio to to receive upfront, and potential milestones and tiered royalty payments BOSTON, November 18, 2024 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a …

CouponFollow Extension

$745
OFF

Ratio Therapeutics Lands $745M Cancer Drug Development Deal …

6 days from now

4 days ago · Ratio Therapeutics has entered into an exclusive worldwide license and collaboration agreement with Novartis Pharma AG to develop a Somatostatin Receptor 2 (SSTR2) …

stocktitan.net

$745
OFF

Novartis Strengthens Radiopharma Leadership With Ratio ... - MSN

6 days from now

Novartis has teamed up with Ratio Therapeutics in a $745m licensing and collaboration agreement to advance radiopharmaceutical therapies. ... This latest partnership follows a …

msn.com

$745
OFF

Novartis Expands Radiopharmaceutical Portfolio With $745M Deal …

6 days from now

5 days ago · Novartis has struck a licensing agreement with Boston-based biotech Ratio Therapeutics, securing global rights to a promising cancer candidate targeting somatostatin …

biopharmatrend.com

$745
OFF

Novartis Invests $745M To Compete With BMS And Lilly In The …

6 days from now

4 days ago · Ratio will lead preclinical development, and once a candidate is selected, Novartis will handle the rest of the development, manufacturing, and commercialization. This …

geneonline.com

$745
OFF

Novartis Continues Push Into Radiopharma With $745M Ratio Deal

6 days from now

5 days ago · With two approved radioligand therapies on its commercial roster and a recent plan to boost its manufacturing for radiotherapeutics, Novartis AG tapped Ratio Therapeutics Inc. in …

bioworld.com

$750
OFF

Ratio Nets Potential $750M Radioligand Cancer Deal With Novartis

6 days from now

4 days ago · Ratio Therapeutics has inked an exclusive worldwide agreement potentially worth $745M with Novartis Pharma AG. The collaboration leverages Ratio’s radioligand therapy …

insideprecisionmedicine.com

$745
OFF

Novartis Strikes Radiopharma Deal With Ratio Worth Up To $745M

6 days from now

4 days ago · Novartis and Ratio Therapeutics announced a collaboration deal worth up to $745 million, focusing on SSTR2 radiotherapeutic cancer treatment. Ratio will receive an …

endpts.com

$745
OFF

Ratio Therapeutics Partners With Novartis For $745M... | DeepNewz

6 days from now

3 days ago · Ratio Therapeutics has entered into an exclusive worldwide license and collaboration agreement with Novartis, potentially valued at $745 million, to develop a radiotherapeutic …

deepnewz.com

FAQs about November 18th, 2024: Ratio Enters License and Collaboration … Coupon?

How much money will ratio receive from Novartis?

Under the terms of the agreement, Ratio will receive combined upfront and potential milestone payments up to $745m, and is eligible to receive tiered royalty payments. Ratio will collaborate with Novartis to drive preclinical activities to research and select an SSTR2-targeting development candidate. ...

Does Novartis offer radioligand therapy for cancer patients?

"Radioligand therapies hold transformative potential for certain forms of cancer, and Novartis is committed to maximizing their impact by continually improving the benefit for patients," said Fiona Marshall, President of Biomedical Research at Novartis. ...

Is ratio partnering with Novartis to develop a new sstr2-targeting therapy?

"The team at Ratio is honored and excited to partner with Novartis on the development of a next-generation SSTR2-targeting therapeutic," said Jack Hoppin, Ph.D., Chief Executive Officer of Ratio. "Together, we aim to develop a best-in-class therapy in the fight against SSTR2-expressing tumors." ...

What will Novartis do with SSTR2?

The collaboration focuses on preclinical research to identify an SSTR2-targeting development candidate, after which Novartis will take the lead on development, manufacturing, and commercialisation. A protein overexpressed in various cancers, SSTR2 is a key target for therapies due to its role in enabling precise and targeted treatment. ...